Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases

PR Newswire April 3, 2018

Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

PR Newswire March 26, 2018

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018

PR Newswire February 12, 2018

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018

PR Newswire February 7, 2018

Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist

PR Newswire February 5, 2018

The Biotechnology Market is Projected to Grow

PR Newswire January 26, 2018

Biotech and Pain Management Therapeutics Segments Projected to Grow

PR Newswire January 12, 2018

Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For Ulcerative Colitis

PR Newswire January 3, 2018

Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs

PR Newswire December 11, 2017

Palatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea

PR Newswire November 21, 2017

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017

PR Newswire November 13, 2017

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017

PR Newswire November 8, 2017

Investor Network: Palatin Technologies, Inc. to Host Earnings Call

Accesswire September 25, 2017

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017

PR Newswire September 25, 2017

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2017 Results; Teleconference and Webcast to be held on September 25, 2017

PR Newswire September 20, 2017

Today's Research Report Coverage on Healthcare Stocks -- AMAG Pharma, IDEXX Laboratories, Palatin Technologies, and Bio-Path

PR Newswire September 20, 2017

Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors

PR Newswire September 12, 2017

Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories

PR Newswire September 6, 2017

Recent Developments in the Pharmaceutical Industry

PR Newswire September 5, 2017

Stock Performance Review on Healthcare Sector -- Palatin Technologies, Centene, Anthem, and AMAG Pharma

PR Newswire June 8, 2017